November 15, 2019
The company discontinued its Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in bladder cancer.
February 12, 2019
Anchiano Therapeutics (NASDAQ:ANCN) has announced it has priced its initial public offering of 2.65 million shares at a price of...
January 15, 2019
Initial public offerings meant to take place are facing a huge barrier due to the ongoing US government shutdown.